Literature DB >> 19631478

Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Ross H Lowe1, Tsadik T Abraham, William D Darwin, Ronald Herning, Jean Lud Cadet, Marilyn A Huestis.   

Abstract

BACKGROUND: Generally, urinary 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCCOOH) after alkaline hydrolysis is monitored to detect cannabis exposure, although last use may have been weeks prior in chronic cannabis users. Delta9-Tetrahydrocannabinol (THC) and 11-hydroxy-THC (11-OH-THC) concentrations in urine following Escherichia coli beta-glucuronidase hydrolysis were proposed as biomarkers of recent (within 8h) cannabis use.
OBJECTIVE: To test the validity of THC and 11-OH-THC in urine as indicators of recent cannabis use.
METHODS: Monitor urinary cannabinoid excretion in 33 chronic cannabis smokers who resided on a secure research unit under 24h continuous medical surveillance. All urine specimens were collected individually ad libidum for up to 30 days, were hydrolyzed with a tandem E. coli beta-glucuronidase/base procedure, and analyzed for THC, 11-OH-THC and THCCOOH by one- and two-dimensional-cryotrap gas chromatography mass spectrometry (2D-GCMS) with limits of quantification of 2.5 ng/mL.
RESULTS: Extended excretion of THC and 11-OH-THC in chronic cannabis users' urine was observed during monitored abstinence; 14 of 33 participants had measurable THC in specimens collected at least 24h after abstinence initiation. Seven subjects had measurable THC in urine for 3, 3, 4, 7, 7, 12, and 24 days after cannabis cessation. 11-OH-THC and THCCOOH were detectable in urine specimens from one heavy, chronic cannabis user for at least 24 days.
CONCLUSION: For the first time, extended urinary excretion of THC and 11-OH-THC is documented for at least 24 days, negating their effectiveness as biomarkers of recent cannabis exposure, and substantiating long terminal elimination times for urinary cannabinoids following chronic cannabis smoking.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19631478      PMCID: PMC2763020          DOI: 10.1016/j.drugalcdep.2009.05.027

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  28 in total

1.  GC/MS and EMIT analyses for delta 9-tetrahydrocannabinol metabolites in plasma and urine of human subjects.

Authors:  L J McBurney; B A Bobbie; L A Sepp
Journal:  J Anal Toxicol       Date:  1986 Mar-Apr       Impact factor: 3.367

2.  Excretion patterns of cannabinoid metabolites after last use in a group of chronic users.

Authors:  G M Ellis; M A Mann; B A Judson; N T Schramm; A Tashchian
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

3.  Persistence of urinary marijuana levels after supervised abstinence.

Authors:  C A Dackis; A L Pottash; W Annitto; M S Gold
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

4.  Human urinary excretion profile after smoking and oral administration of [14C]delta 1-tetrahydrocannabinol.

Authors:  E Johansson; H K Gillespie; M M Halldin
Journal:  J Anal Toxicol       Date:  1990 May-Jun       Impact factor: 3.367

5.  Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.

Authors:  E Johansson; M M Halldin
Journal:  J Anal Toxicol       Date:  1989 Jul-Aug       Impact factor: 3.367

6.  Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Authors:  E Johansson; M M Halldin; S Agurell; L E Hollister; H K Gillespie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV.

Authors:  Albert D Fraser; David Worth
Journal:  Forensic Sci Int       Date:  2004-07-16       Impact factor: 2.395

8.  Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS.

Authors:  P M Kemp; I K Abukhalaf; J E Manno; B R Manno; D D Alford; G A Abusada
Journal:  J Anal Toxicol       Date:  1995-09       Impact factor: 3.367

9.  Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users.

Authors:  P Kelly; R T Jones
Journal:  J Anal Toxicol       Date:  1992 Jul-Aug       Impact factor: 3.367

10.  Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol. Study III. A Delta9-THC-COOH to creatinine ratio study.

Authors:  Albert D Fraser; David Worth
Journal:  Forensic Sci Int       Date:  2003-11-26       Impact factor: 2.395

View more
  35 in total

1.  Cannabinoid hyperemesis: a case series of 98 patients.

Authors:  Douglas A Simonetto; Amy S Oxentenko; Margot L Herman; Jason H Szostek
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chim Acta       Date:  2012-07-06       Impact factor: 3.786

3.  Rapid elimination of Carboxy-THC in a cohort of chronic cannabis users.

Authors:  John Lewis; Anna Molnar; David Allsop; Jan Copeland; Shanlin Fu
Journal:  Int J Legal Med       Date:  2015-08-02       Impact factor: 2.686

Review 4.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

5.  Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.

Authors:  Marilyn A Huestis; Cristina Sempio; Matthew N Newmeyer; Maria Andersson; Allan J Barnes; Osama A Abulseoud; Benjamin C Blount; Jennifer Schroeder; Michael L Smith
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

Review 6.  The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.

Authors:  Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2020-04-26       Impact factor: 4.492

7.  Cannabis-related hippocampal volumetric abnormalities specific to subregions in dependent users.

Authors:  Yann Chye; Chao Suo; Murat Yücel; Lauren den Ouden; Nadia Solowij; Valentina Lorenzetti
Journal:  Psychopharmacology (Berl)       Date:  2017-04-19       Impact factor: 4.530

8.  Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Authors:  Dayong Lee; Erin L Karschner; Garry Milman; Allan J Barnes; Robert S Goodwin; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-11-10       Impact factor: 4.492

Review 9.  Cannabis in sport: anti-doping perspective.

Authors:  Marilyn A Huestis; Irene Mazzoni; Olivier Rabin
Journal:  Sports Med       Date:  2011-11-01       Impact factor: 11.136

10.  In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis.

Authors:  Nathalie A Desrosiers; Dayong Lee; Karl B Scheidweiler; Marta Concheiro-Guisan; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-12-01       Impact factor: 4.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.